NASDAQ:MBX - Nasdaq - US55287L1017 - Currency: USD
10.88
-0.95 (-8.03%)
The current stock price of MBX is 10.88 USD. In the past month the price decreased by -7.25%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
MBX Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Carmel, Indiana and currently employs 36 full-time employees. The company went IPO on 2024-09-13. MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
MBX BIOSCIENCES INC
12406 Horesham Street
Carmel INDIANA US
Employees: 36
Company Website: https://mbxbio.com/
Phone: 13179893100
The current stock price of MBX is 10.88 USD. The price decreased by -8.03% in the last trading session.
The exchange symbol of MBX BIOSCIENCES INC is MBX and it is listed on the Nasdaq exchange.
MBX stock is listed on the Nasdaq exchange.
8 analysts have analysed MBX and the average price target is 37.99 USD. This implies a price increase of 249.22% is expected in the next year compared to the current price of 10.88. Check the MBX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MBX BIOSCIENCES INC (MBX) has a market capitalization of 363.61M USD. This makes MBX a Small Cap stock.
MBX BIOSCIENCES INC (MBX) currently has 36 employees.
MBX BIOSCIENCES INC (MBX) has a resistance level at 12.35. Check the full technical report for a detailed analysis of MBX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MBX does not pay a dividend.
MBX BIOSCIENCES INC (MBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.46).
The outstanding short interest for MBX BIOSCIENCES INC (MBX) is 12.42% of its float. Check the ownership tab for more information on the MBX short interest.
ChartMill assigns a fundamental rating of 3 / 10 to MBX. While MBX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months MBX reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS decreased by -24.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.94% | ||
ROE | -29.07% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 88% to MBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.